Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

4 year outcomes in a prospective evaluation of transcatheter mitral valve-in-valve, valve-in-ring and valve-in-mitral annular calcification: results from the MITRAL trial
Eleid, Mackram F. , Kodali, S., Palacios, Igor F. , Makkar, Rajendra, Satler, Lowell F. , Kaptzan, T, Lewis, B , Thaden, J, Oh, J K, Rihal, C., Guerrero, Mayra , Wang, Dee Dee , Pursnani, Amit , George, Isaac , Kaptzan, Tatiana, O’Neill, William W.

Mayo Clinic

European Heart Journal | October 15, 2022 | Volume: 43 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehac544.2120 Get It

Abstract Background The MITRAL Trial (Mitral Implantation of TRAnscatheter vaLves) evaluates the safety and feasibility of balloon-expandable aortic transcatheter heart valves in patients with severe mitral valve disease with mitral annular calcification (MAC), failed surgical rings or failed bioprostheses. Purpose We sought to evaluate 4-year outcomes of patients enrolled in the MITRAL trial. Methods This is a prospective study that enrolled 91 high surgical risk patients at 13 sites in the U.S. 30 patients underwent Mitral Valve-in-Valve (MViV), 30 Valve-in-Ring (MViR) and 31 Valve-in-MAC (ViMAC). 4-year outcomes of these patients were evaluated in this analysis. Primary endpoints and key serious adverse events including deaths were adjudicated by an independent Clinical Events Committee. Cardiac computed tomography (CT) and echocardiographic images were evaluated by independent CT and Echocardiographic Core Laboratories. Results Mean age was 74.3±8.9 years. Most patients undergoing MViV and ViMAC were female (MVIV=63.3%, MViR=36.7% and ViMAC=71%). Mean STS score was 9.2±6.6% (MViV 10.2±6.5%, MViR 8.7±4.7%, ViMAC=8.6±8.2%). All-cause mortality at 4 years was higher for ViMAC and MViR: MViV=6.9% (cardiovascular 3.4%), MViR=48.1% (cardiovascular 18.5%), ViMAC=51.9% (cardiovascular 29.6%), p=0.002 (Figure 1). At 4 years, all survivors had ≤1+ mitral regurgitation and most had none or trace mitral regurgitation (MViV=87.5, MViR=33.3% and ViMAC=100%). Mean mitral valve gradients remained stable (MViV=5.9±2.2 mmHg, MViR= 6.6±5.1 mmHg, ViMAC=5.1±1.0 mmHg), Figure 2. Most survivors experienced significant improvement of symptoms and were in NYHA class I-II at 4-year follow-up (MViV=78.9%, MViR=66.7% and ViMAC=66.7%). Conclusions MViV is associated with excellent outcomes at 4 years. MViR and ViMAC were associated with higher mortality at 4 years. However, most survivors in all groups experienced sustained improvement of symptoms and stable THV performance at 4 years. Whether survival bias had an impact on THV performance and improved symptoms at follow-up is not known and deserves further evaluation. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Unrestricted Research Grant from Edwards Lifesciences.
Amyloidosis-related echo features and mortality in patients with multiple myeloma
Cui, Zhi Min , Hanif, Waqas , Apple, Samuel J. , Zhang, L, Tauras, James M. , Braunschweig, Ira , Wang, Y, García, Mario J. , Castagna, Francesco , Kaur, Gurbakhash , Janakiram, Murali , Fang, Yanan , Pellikka, Patricia A. , Shah, Nishi , Slipczuk, Leandro

Mayo Clinic

European Heart Journal | October 14, 2022 | Volume: 43 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehac544.050 Get It

Abstract Background/Introduction Patients with multiple myeloma (MM) are at increased risk of developing AL amyloidosis. It was determined by screening fat pad and bone marrow biopsy that 38% MM patients had amyloidosis at time of diagnosis and the majority were asymptomatic (1). However, whether amyloidosis-related echo features in MM affect survival remains unknown (1, 2). Purpose The goals of our study are to: 1) characterize prevalence of amyloidosis-related echo features in patients with multiple myeloma, 2) investigate whether decrease in longitudinal strain affect survival outcomes. Methods Patients diagnosed with MM between Jan 1, 2000 and Dec 31, 2017 at our institution were identified through Clinical Looking Glass. Those with echo within 1 year after myeloma diagnosis and left ventricular ejection fraction (LVEF) greater than 40% were included. Global longitudinal strain (GLS) and LVEF measurements were done using EchoGo (Ultromics, Oxford, UK). The average of GLS obtained from apical 4-chamber and apical 2-chamber views was used for analysis, with decreased GLS defined as absolute value less than 18%. Statistical analysis was conducted with STATA13, using Chi square test and Kruskal-Wallis for univariable analysis and Cox regression model for survival analysis. Results From a total cohort of 909 patients, 252 met inclusion criteria, of which 59 (23.4%) patients had decreased average GLS (see Table 1). Patients' mean age was 63±11 years, 44.8% were male and most were Black (42.7%) and the rest Hispanic (33.3%) and White (7.9%). Median follow up time was 4.25 years. The group with decreased GLS had lower percentage of females (22% vs 51.8%, p<0.01), higher percentage of previous MI (11.9% vs 1.6%, p<0.01) and more prior diagnosis of heart failure (20.3% vs 1.6%, p<0.01). Among patients with decreased GLS, five-year mortality rate was 63.3% compared to 46.0% in those with preserved GLS (p<0.036). Median survival time was 3.9 years among those with reduced GLS and 4.3 years in those without (see Figure 1; p<0.01). Reduced GLS correlated with decreased survival (HR 1.6, p=0.03) even after adjusting for demographic variables (age, gender, race), history of MI, history of CHF, Charlson comorbidity index, myeloma RISS stage, and LVEF (≥50% vs 40–50%). Forty-seven (18.6%) patients had end diastolic inter-ventricular septum (IVSd) thickness ≥1.2cm. Median GLS in patients with increased IVSd thickness was 19% compared to 21% in those without (p=0.01). Nine patients had the apical sparing strain pattern for amyloidosis. Total of 158 patients had bone marrow specimen stained with Congo-red with 7 (4.4%) testing positive. Median GLS was 19% in the group staining positive for Congo-red compared 21% in the group with negative stain (p=0.03). Conclusions Decrease in GLS on baseline echo correlates with increased mortality in patients with MM and may be due to subclinical cardiac amyloidosis. Funding Acknowledgement Type of funding sources: None.
High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course
O'Donoghue, Darragh, Truong, Huong L. , Finnes, Heidi D. , May, Heather P. , Ansell, Stephen M. , Bennani, N. Nora , Habermann, Thomas M. , Inwards, David J. , Johnston, Patrick B. , Khurana, Arushi , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Porrata, Luis F. , Thanarajasingam, Gita , Thompson, Carrie A. , O'Donoghue, Darragh F, Personett, Heather A. , Ansell, Stephen M , Bennani, N Nora , Habermann, Thomas , Micallef, Ivana N , Nowakowski, Grzegorz S , Paludo, Jonas , Thanarajasingam, Gita , Thompson, Carrie A , Villasboas, Jose Caetano , Wang, Yucai , Witzig, T.E. , Leung, Nelson , McDonald, Jennifer S. , Lin, Yi , Paludo, Jonas , Villasboas, José C. , Wang, Yucai , Witzig, Thomas E. , Leung, Nelson

Mayo Clinic

JCO Oncology Practice | October 14, 2022 | Volume: 18 | Issue: 12 | Pages: e1908-e1917

10.1200/op.22.00182 | PMID 36240468 Get It

PURPOSE:High-dose methotrexate (HDMTX; > 500 mg/m2) is an important component of lymphoma therapy. Serum MTX monitoring at 48 hours is the standard approach to identify those at increased risk of developing MTX toxicity. Our aim was to characterize the incidence of complications and their association with MTX levels.METHODS:A retrospective review of our institutional electronic medical record was conducted to identify patients with lymphoma who received HDMTX between January 1, 2002, and December 31, 2018. We characterized the incidence of acute kidney injury (AKI), intensive care unit (ICU) admission, length of hospital stay (LOS), and 30-day mortality across 48-hour MTX levels. To establish an association between 48-hour MTX levels and the complications listed, we performed chi-square analysis for dichotomous variables and Kruskal-Wallis for nonparametric data. Receiver operator characteristic curve analysis was performed to identify the MTX level where AKI grade ≥ 2 was more likely. Multivariate logistic regression analysis was performed to identify risk factors for this MTX level.RESULTS:We identified 642 patients with 2,804 cycles of HDMTX. The incidence of AKI was 19.1% with AKI grade ≥ 2 making up 21% of cases. Rates of AKI, ICU admission, and 30-day mortality are associated with elevated 48-hour MTX levels. There was a significant increase in median LOS with elevated MTX levels ( P < .001). Receiver operator characteristic curve analysis for AKI grade ≥ 2 demonstrated a 48-hour MTX level threshold of 1.28 μmol/L. Multivariate logistic regression analysis revealed age, male sex, elevated body surface area, higher MTX dose, monotherapy, and first cycle as independent factors.CONCLUSION:Elevated MTX levels are associated with a significant increased rate of AKI, ICU admission, prolonged LOS, and 30-day mortality. Elevated 48-hour MTX levels, particularly > 1.28 μmol/L, should alert clinicians for complications and to initiate measures to reduce MTX levels.
Leveraging machine learning to ascertain the implications of preoperative body mass index on surgical outcomes for 282 patients with preoperative obesity and lumbar spondylolisthesis in the Quality Outcomes Database
Agarwal, Nitin , Chan, Andrew K. , Shabani, Saman , Bisson, Erica F. , Bydon, Mohamad , Glassman, Steven D. , Foley, Kevin T. , Shaffrey, Christopher I. , Potts, Eric A. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Park, Paul , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S. , Haid, Regis W., Chou, Dean , Mummaneni, Praveen V. , Aabedi, Alexander A. , Letchuman, Vijay

Mayo Clinic

Journal of Neurosurgery: Spine | October 14, 2022 | Volume: 38 | Issue: 2 | Pages: 182-191

10.3171/2022.8.spine22365 | PMID 36208428 Get It

OBJECTIVE Prior studies have revealed that a body mass index (BMI) ≥ 30 is associated with worse outcomes following surgical intervention in grade 1 lumbar spondylolisthesis. Using a machine learning approach, this study aimed to leverage the prospective Quality Outcomes Database (QOD) to identify a BMI threshold for patients undergoing surgical intervention for grade 1 lumbar spondylolisthesis and thus reliably identify optimal surgical candidates among obese patients. METHODS Patients with grade 1 lumbar spondylolisthesis and preoperative BMI ≥ 30 from the prospectively collected QOD lumbar spondylolisthesis module were included in this study. A 12-month composite outcome was generated by performing principal components analysis and k-means clustering on four validated measures of surgical outcomes in patients with spondylolisthesis. Random forests were generated to determine the most important preoperative patient characteristics in predicting the composite outcome. Recursive partitioning was used to extract a BMI threshold associated with optimal outcomes. RESULTS The average BMI was 35.7, with 282 (46.4%) of the 608 patients from the QOD data set having a BMI ≥ 30. Principal components analysis revealed that the first principal component accounted for 99.2% of the variance in the four outcome measures. Two clusters were identified corresponding to patients with suboptimal outcomes (severe back pain, increased disability, impaired quality of life, and low satisfaction) and to those with optimal outcomes. Recursive partitioning established a BMI threshold of 37.5 after pruning via cross-validation. CONCLUSIONS In this multicenter study, the authors found that a BMI ≤ 37.5 was associated with improved patient outcomes following surgical intervention. These findings may help augment predictive analytics to deliver precision medicine and improve prehabilitation strategies.
Evaluation of Bivalirudin Dosing in Pediatric Extracorporeal Membrane Oxygenation with Renal Insufficiency or Renal Replacement Therapy
Seelhammer, Troy G. , Yabrodi, Mouhammad, Beshish, Asaad , Byrnes, Jonathan W. , Hall, James O., Wang, Lu , Hamzah, Mohammed , Hamzah, Mohammed , Niebler, Robert A.

Mayo Clinic

ASAIO Journal | October 14, 2022 | Volume: 68 | Issue: 11 | Pages: e196-e203

10.1097/mat.0000000000001818 | PMID 36229032 Get It

Bivalirudin offers several important advantages of relevance to the management of extracorporeal membrane oxygenation (ECMO) patients. This multicenter retrospective analysis evaluated the bivalirudin dosing in pediatric ECMO and correlated these doses with the severity of renal dysfunction. A total of 75 patients were included in this analyses: estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73 m2 (n = 29), eGFR 30–60 (n = 18), eGFR < 30 (n = 28), and of those 23 were on renal replacement therapy (RRT). The initial bivalirudin dose used to reach therapeutic anticoagulation in patients with eGFR > 60 was significantly higher than the dose required in those with renal impairment (0.25 mg/kg/hr in patients with eGFR > 60 and 0.19 mg/kg/hr in patients on RRT, 0.18 mg/kg/hr in patients with eGFR 30–60 and 0.13 mg/kg/hr in patients with eGFR < 30 with no RRT). Progressive dose escalations (two to threefold increase) were required to maintain therapeutic range over the initial 4 days of ECMO that coincided with improving renal creatinine clearance during that same time period. Establishing an initial starting dose of bivalirudin contingent upon eGFR is essential for the rapid achievement of target anticoagulation intensity. Further dose adjustments guided by laboratory monitoring is necessary given the dynamic changes in creatinine clearance following ECMO initiation.
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Wang‐Gillam, Andrea , McWilliams, Robert R. , Suresh, Rama , Lockhart, A. Craig , Brown, Amberly , Breden, Marcus , Belle, Jad I. , Herndon, John M. , Bogner, Savannah J. , Tan, Benjamin , Boice, Nicholas , Acharya, Abhi , Abdiannia, Mina , Yoon, Harry H. , Zhu, Mojun , Aranha, Olivia , Herzog, Brett H. , Lim, Kian-Huat , McWilliams, Robert R , Suresh, Rama , Lockhart, Albert C , Brown, Amberly , Breden, Marcus , Belle, Jad I , Herndon, John , Bogner, Savannah J , Pedersen, Katrina , Tan, Benjamin , Boice, Nicholas , Acharya, Abhi , Abdiannia, Mina , Gao, Feng , Yoon, Harry H , Zhu, Mojun , Trikalinos, Nikolaos A , Ratner, Lee , Aranha, Olivia , Hawkins, William G , Herzog, Brett H , DeNardo, David G , Wang-Gillam, Andrea , Pedersen, Katrina S. , Gao, Feng , Trikalinos, Nikolaos A. , Ratner, Lee

Mayo Clinic

Clinical Cancer Research | October 13, 2022 | Volume: 28 | Issue: 24 | Pages: 5254-5262

10.1158/1078-0432.ccr-22-0308 | PMID 36228156 Get It

Abstract Purpose: Targeting focal adhesion kinase (FAK) renders checkpoint immunotherapy effective in pancreatic ductal adenocarcinoma (PDAC) mouse model. Defactinib is a highly potent oral FAK inhibitor that has a tolerable safety profile. Patients and Methods: We conducted a multicenter, open-label, phase I study with dose escalation and expansion phases. In dose escalation, patients with refractory solid tumors were treated at five escalating dose levels of defactinib and gemcitabine to identify a recommended phase II dose (RP2D). In expansion phase, patients with metastatic PDAC who progressed on frontline treatment (refractory cohort) or had stable disease (SD) after at least 4 months of standard gemcitabine/nab-paclitaxel (maintenance cohort) were treated at RP2D. Pre- and posttreatment tumor biopsies were performed to evaluate tumor immunity. Results: The triple drug combination was well-tolerated, with no dose-limiting toxicities. Among 20 treated patients with refractory PDAC, the disease control rate (DCR) was 80%, with one partial response (PR) and 15 SDs, and the median progression-free survival (PFS) and overall survival (OS) were 3.6 and 7.8 months, respectively. Among 10 evaluable patients in the maintenance cohort, DCR was 70% with one PR and six SDs. Three patients with SD came off study due to treatment- or disease-related complications. The median PFS and OS on study treatment were 5.0 and 8.3 months, respectively. Conclusions: The combination of defactinib, pembrolizumab, and gemcitabine was well-tolerated and safe, had promising preliminary efficacy, and showed biomarker activity in infiltrative T lymphocytes. Efficacy of this strategy may require incorporation of more potent chemotherapy in future studies.
Leveraging a pharmacogenomics knowledgebase to formulate a drug response phenotype terminology for genomic medicine
Zhao, Yiqing , Brush, Matthew , Wang, Chen , Wagner, Alex H. , Freimuth, Robert R. , Freimuth, Robert R , Wang, Chen , Wagner, Alex H , Liu, Hongfang

Mayo Clinic

Bioinformatics | October 10, 2022 | Volume: 38 | Issue: 23 | Pages: 5279-5287

10.1093/bioinformatics/btac646 | PMID 36222570 Get It

Abstract Motivation Despite the increasing evidence of utility of genomic medicine in clinical practice, systematically integrating genomic medicine information and knowledge into clinical systems with a high-level of consistency, scalability and computability remains challenging. A comprehensive terminology is required for relevant concepts and the associated knowledge model for representing relationships. In this study, we leveraged PharmGKB, a comprehensive pharmacogenomics (PGx) knowledgebase, to formulate a terminology for drug response phenotypes that can represent relationships between genetic variants and treatments. We evaluated coverage of the terminology through manual review of a randomly selected subset of 200 sentences extracted from genetic reports that contained concepts for ‘Genes and Gene Products’ and ‘Treatments’. Results Results showed that our proposed drug response phenotype terminology could cover 96% of the drug response phenotypes in genetic reports. Among 18 653 sentences that contained both ‘Genes and Gene Products’ and ‘Treatments’, 3011 sentences were able to be mapped to a drug response phenotype in our proposed terminology, among which the most discussed drug response phenotypes were response (994), sensitivity (829) and survival (332). In addition, we were able to re-analyze genetic report context incorporating the proposed terminology and enrich our previously proposed PGx knowledge model to reveal relationships between genetic variants and treatments. In conclusion, we proposed a drug response phenotype terminology that enhanced structured knowledge representation of genomic medicine. Supplementary information Supplementary data are available at Bioinformatics online.
Rationale and Design for the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study
Hart, Phil A. , Park, Walter G. , Dyer, Anne‐Marie , Andersen, Dana K. , Buxbaum, James , Conwell, Darwin L. , Dungan, Kathleen , Easler, Jeffrey J. , Fogel, Evan L. , Greenbaum, Carla J. , Kalyani, Rita R. , Korc, Murray , Kozarek, Richard A. , Laughlin, Maren R. , Lee, Peter J. , Maranki, Jennifer , Speake, Cate, Toledo, Frederico G. S. , Trikudanathan, Guru , Vege, Santhi Swaroop , Yazıcı, Cemal , Zaheer, Atif , Forsmark, Christopher E., Yadav, Dhiraj , Papachristou, Georgios I. , Chinchilli, Vernon M , Afghani, Elham , Akshintala, Venkata S. , Pandol, Stephen J. , Phillips, Anna Evans , Serrano, José , Singh, Vikesh K. , Speake, Cate , Tirkes, Temel , Wang, Ming , Bellin, Melena D.

Mayo Clinic

Pancreas | October 7, 2022 | Volume: 51 | Issue: 6 | Pages: 568-574

10.1097/mpa.0000000000002079 | PMID 36206460 Get It

Abstract Acute pancreatitis (AP) is a disease characterized by an acute inflammatory phase followed by a convalescent phase. Diabetes mellitus (DM) was historically felt to be a transient phenomenon related to acute inflammation; however, it is increasingly recognized as an important late and chronic complication. There are several challenges that have prevented precisely determining the incidence rate of DM after AP and understanding the underlying mechanisms. The DREAM (Diabetes RElated to Acute Pancreatitis and its Mechanisms) Study is a prospective cohort study designed to address these and other knowledge gaps to provide the evidence needed to screen for, prevent, and treat DM after AP. In the following article, we summarize literature regarding the epidemiology of DM after AP and provide the rationale and an overview of the DREAM study.
A noncoding single-nucleotide polymorphism at 8q24 drives IDH1 -mutant glioma formation
Yanchus, Connor , Drucker, Kristen , Kollmeyer, Thomas M. , Tsai, Ricky , Winick‐Ng, Warren , Liang, Minggao , Malik, Ahmad , Pawling, Judy , Lorenzo, Silvana B. De, Ali, Asma, Decker, Paul A. , Kosel, Matt, Panda, Arijit , Al‐Zahrani, Khalid N. , Jiang, Lingyan , Browning, Jared , Lowden, Christopher , Hernández, J. Javier , Gosio, Jessica , Loganathan, Sampath K. , Berman, Jacob M. , Trcka, Daniel , Michealraj, Kulandaimanuvel Antony , Fortin, Jérôme, Carson, Brittany B. , Hollingsworth, Ethan W. , Jacinto, Sandra , Mazrooei, Parisa, Zhou, Lily , Elia, Andrew , Lupien, Mathieu , Murphy, Daniel J. , Wang, Liguo , Abyzov, Alexej , Dennis, James W. , Maass, Philipp G. , Wrensch, Margaret , Mak, Tak W. , Visel, Axel , Wrana, Jeffrey L. , Zadeh, Gelareh , Eckel‐Passow, Jeanette E. , Attisano, Liliana , Pombo, Ana , Kvon, Evgeny Z. , Jenkins, Robert B. , Schramek, Daniel , Drucker, Kristen L , De Lorenzo, Silvana B, Kosel, Matt L, Browning, Jared W L , Lowden, Chris , Hernandez, J Javier , Ahmed, Musaddeque , Loganathan, Sampath Kumar , Berman, Jacob , Trcka, Daniel , Hollingsworth, Ethan W , Elia, Andrew , Lupien, Mathieu , He, Housheng Hansen , Wang, Liguo , Abyzov, Alexej , Dennis, James W , Maass, Philipp G , Wilson, Michael D , Wrensch, Margaret , Mak, Tak , Pennacchio, Len A , Dickel, Diane E , Visel, Axel , Wrana, Jeffrey , Dirks, Peter , Eckel-Passow, Jeanette E , Attisano, Liliana , Pombo, Ana , Ida, Cristiane M , Kvon, Evgeny Z , Jenkins, RB , Schramek, Daniel , Kollmeyer, Thomas , Murphy, Daniel J , Decker, Paul A. , Kosel, Matthew , Geuenich, Michael J. , Ahmed, Musaddeque , He, Housheng Hansen , Campbell, Kieran R. , Wilson, Michael D. , Lachance, Daniel Honore , Wiencke, John K. , Taylor, Michael D. , Ida, Cristiane M.

Mayo Clinic

Science | October 6, 2022 | Volume: 378 | Issue: 6615 | Pages: 68-78

10.1126/science.abj2890 | PMID 36201590 Get It

Establishing causal links between inherited polymorphisms and cancer risk is challenging. Here, we focus on the single-nucleotide polymorphism rs55705857, which confers a sixfold greater risk of isocitrate dehydrogenase ( IDH) –mutant low-grade glioma (LGG). We reveal that rs55705857 itself is the causal variant and is associated with molecular pathways that drive LGG. Mechanistically, we show that rs55705857 resides within a brain-specific enhancer, where the risk allele disrupts OCT2/4 binding, allowing increased interaction with the Myc promoter and increased Myc expression. Mutating the orthologous mouse rs55705857 locus accelerated tumor development in an Idh1 R132H -driven LGG mouse model from 472 to 172 days and increased penetrance from 30% to 75%. Our work reveals mechanisms of the heritable predisposition to lethal glioma in ~40% of LGG patients.